Neurocrine Biosciences, Inc.
NBIX
$108.31
$1.311.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.81% | 25.72% | 26.69% | 23.99% | 26.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.81% | 25.72% | 26.69% | 23.99% | 26.76% |
| Cost of Revenue | 26.53% | 22.55% | 22.36% | 18.06% | 24.17% |
| Gross Profit | 24.00% | 27.27% | 28.78% | 26.92% | 28.02% |
| SG&A Expenses | 15.05% | 10.18% | 8.94% | 11.74% | 17.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.70% | 15.22% | 14.24% | 14.26% | 20.38% |
| Operating Income | 44.12% | 69.10% | 84.96% | 70.68% | 58.55% |
| Income Before Tax | 46.34% | 107.15% | 90.90% | 426.79% | 55.26% |
| Income Tax Expenses | 75.61% | 123.19% | 86.66% | 297.62% | 38.72% |
| Earnings from Continuing Operations | 36.68% | 102.04% | 92.29% | 477.66% | 61.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.68% | 102.04% | 92.29% | 477.66% | 61.62% |
| EBIT | 44.12% | 69.10% | 84.96% | 70.68% | 58.55% |
| EBITDA | 43.26% | 66.89% | 81.92% | 68.28% | 57.26% |
| EPS Basic | 33.68% | 96.91% | 87.53% | 458.75% | 57.89% |
| Normalized Basic EPS | 43.71% | 68.81% | 89.51% | 80.71% | 73.25% |
| EPS Diluted | 35.69% | 101.13% | 91.95% | 508.74% | 58.81% |
| Normalized Diluted EPS | 43.60% | 68.38% | 88.94% | 79.36% | 73.32% |
| Average Basic Shares Outstanding | 2.74% | 2.88% | 2.61% | 2.31% | 2.09% |
| Average Diluted Shares Outstanding | 3.49% | 3.73% | 3.48% | 3.75% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
